Edward Dyson



Ed counsels public and pre-IPO private companies, investors, entrepreneurs and underwriters on London Stock Exchange, Nasdaq and NYSE capital markets transactions.

He also regularly advises on domestic and cross-border public and private M&A deals, venture capital and growth equity financings, strategic ventures, direct listings, introductions, block trades, demergers/spin-outs, dual-listings, reverse mergers, de-SPACs/reverse takeovers, class and related party transactions, share buy-backs, transfers of listing segment and other corporate matters.

His broad industry experience includes working with companies in the energy, financial services, healthcare and life sciences, logistics, retail, media, natural resources and technology sectors.

  • IPOs / Direct Listings / Follow-ons:

    • Kistos Holdings plc on its AIM Direct Listing
    • Zamaz plc on its Main Market Direct Listing
    • OKYO Pharma Limited on its Main Market IPO, Nasdaq dual-listing and global follow-ons
    • Codex Acquisitions plc on its Main Market IPO
    • URA Holdings plc on its Main Market IPO
    • Hamak Gold Limited on its Main Market IPO
    • VEF AB on its First North to Nasdaq Stockholm Main Market listing step-up
    • Tiziana Life Sciences Limited on its AIM to Main Market listing step-up, Nasdaq dual-listing, redomiciliation and global follow-ons
    • [email protected] Capital plc on various Main Market follow-ons
    • Attica Bank S.A. on various Athens Stock Exchange follow-ons
    • AccuStem Sciences Inc. on its demerger and US OTC listing
    • Farmacosmo S.p.A. on its Euronext Growth Milan IPO
    • Heptares Therapeutics Limited on the Nasdaq IPO of Centessa Pharmaceuticals plc
    • Hummingbird Ventures on the Main Market IPO and Standard listing of Deliveroo plc
    • Endava plc on its NYSE IPO
    • Renalytix AI plc on its demerger, AIM IPO and Nasdaq dual-listing
    • the underwriters on the Nasdaq IPOs of Compass Pathways plc, Horizon Discovery plc (aborted), Bicycle Therapeutics plc, Kymab Limited (aborted) and Mereo BioPharma Group plc (aborted)
    • Autolus Therapeutics plc and Nightstar Therapeutics plc on their Nasdaq IPOs
    • Scancell Holdings plc on various AIM follow-ons
    • Realm Therapeutics plc on its direct dual-listing on Nasdaq and subsequent AIM delisting
    • B&M European Value Retail S.A. on its Main Market IPO
    • the underwriters on the Main Market introduction of Metro Bank plc

    M&A / De-SPACs:

    • Kistos plc on its de-SPAC of Tulip and proposed takeover of Serica Energy plc
    • National World plc on its Main Market IPO, de-SPAC of JPI Media and possible offer for Reach plc
    • Pires Investments plc on its proposed takeover by Tern plc
    • VNV Global on the Nasdaq de-SPACs of Swvl with Queen's Gambit Growth Capital and Gett with Rosecliff Acquisition Corp I
    • Kinnevik on the NYSE de-SPAC of Babylon Health with Alkuri Global Acquisition Corp.
    • Realm Therapeutics plc on its recommended takeover by Essa Pharma Inc. by way of scheme of arrangement
    • RockRose Energy plc on its readmission to listing on the Main Market following the reverse takeover of certain North Sea interests acquired from Marathon Oil
    • MightyHive Inc. on its acquisition by S4 Capital plc
    • Just Retirement Group plc on its standby underwritten follow-on, merger with Partnership Assurance Group plc and Main Market introduction of the combined entity, Just Group plc

    Private Capital / Strategic Transactions:

    • FOMTECH Limited (Floww) on its Series B financing and strategic partnership to create a global private capital market with London Stock Exchange Group
    • Metro Africa Xpress Inc. on its Series B financing
    • the financial advisers on a convertible loan note financing by Hawkwing plc
    • Sosei Group Corporation on its collaboration and licensing agreements with Neurocrine Biosciences Inc., Eli Lilly and Co. and AbbVie Inc.

    Please note: Ed's experience includes that prior to joining Orrick.